New treatments to solve global antibiotic crisis could reach the market by 2020
New ARB technology rejuvenates existing antibiotics to outsmart antibiotic resistance.
Helperby Therapeutics has developed a novel answer to the clear and present danger of antimicrobial resistance - Antibiotic Resistance Breakers (ARBs).
Doctors increasingly rely on last resort antibiotics such as carbapenems and colistin, but as harmful bacteria continue to mutate, this final line of resistance will eventually fail.
Helperby’s solution to this critical problem is Antibiotic Resistance Breakers - novel technology that rejuvenates existing antibiotics into long-term effective combination therapies.
The World Health Organisation (WHO) has identified the immediate threat from three critical priority pathogens for which there is currently limited antibiotic protection:
The most dangerous bacteria are CRE, causing severe and often fatal infections such as septicaemia and pneumonia. CRE has spread from Asia into Europe and the US, is epidemic and doubles every 2 years.
Helperby’s ARB rejuvenate existing antibiotics, enabling them to puncture the tough cell wall of CRE and other evolving superbugs to allow existing last-resort antibiotics to effectively do their work. The ARB rejuvenation process can be performed repeatedly on different combinations of existing antibiotics to outsmart resistance.
“New classes of antibiotics are difficult to develop, and none have been marketed for over 30 years,” said Prof Anthony Coates, Chief Scientific Officer of Helperby Therapeutics. “It is therefore imperative we keep existing antibiotics working.”
“We are one of only six companies in the world that have new antibiotics in clinical development which are potentially effective against all three of WHO’s critical priority pathogens.”
ARBs are novel, effective and transferable, potentially producing many variants of new antibiotic combination. One ARB can be applied to multiple different classes of antibiotics, reducing the size, time and resource in Phase III clinical trials normally required for new chemical entities.
Importantly, Helperby’s solution meets WHO's four innovation criteria for effective new antibiotic protection:
Helperby has two formats of ARB combination currently in development, in six programs; of these three are in clinical trials.
“Helperby’s Antibiotic Resistance Breakers are an imminent solution to all three of the critical priority pathogens as identified by the WHO,” added Professor Coates. “We are potentially just 3–5 years away from the market.”
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance